Survival predictors in unresectable stage III NSCLC treated with induction chemoimmunotherapy: a real-world multicenter study of treatment cycles, response, and maintenance duration
BACKGROUND: Optimal integration of induction chemoimmunotherapy with definitive chemoradiotherapy (CRT) and maintenance immunotherapy for unresectable stage III NSCLC remains undefined. METHODS: This multicenter retrospective study included 321 patients who received induction chemoimmunotherapy followed by CRT with or without maintenance immune checkpoint inhibitors (ICIs). Landmark survival from radiotherapy completion was used to avoid guarantee-time bias. RESULTS: Patients receiving 1-2 induction cycles showed numerically longer median PFS (28.0 months) than those with 3-4 (24.6) or >4 cycles (14.2; log-rank p = 0.179), but this trend was confounded by higher concurrent CRT rates in the 1-2 cycle group (74.5%vs. 47.1% vs. 33.7%). After propensity-score matching, the response-related survival advantage was attenuated (HR for PFS 0.70, p = 0.079). In matched analyses, maintenance ICI was associated with improved PFS (25.2 vs. 8.9 months; HR 0.47) and OS (NR vs. 22.0 months; HR 0.24) (both p < 0.001). An exploratory data-driven analysis suggested that >9 maintenance cycles yielded further PFS (HR 0.23) and OS (HR 0.17) benefits. CONCLUSION: In this real-world cohort, induction cycle number did not significantly affect survival; the apparent advantage of 1-2 cycles was likely confounded. Early radiographic response was not an independent predictor after matching. Maintenance ICI was associated with improved outcomes, and >9 cycles showed additional benefit, though with potential bias. These findings provide hypotheses for prospective trial design.
Authors
- Hao Zhou (ORCID: https://orcid.org/0000-0002-5012-7849)
- Liangxue Hou
- Zewen Song (ORCID: https://orcid.org/0000-0002-9685-0725)
- Yong Shi
- Wenyan Pan (ORCID: https://orcid.org/0000-0003-0624-0390)
- Xuanyan Hu
- Chaoyuan Liu
- Yaoxiong Xia
- Hao Hu (ORCID: https://orcid.org/0009-0005-2468-5483)
- Yun Xiang Qi
- Wei Bai
- Pan Xi
Institutions
- Central South University (CN)
- Jishou University (CN)
- University of Electronic Science and Technology of China (CN)
- Shanxi Medical University (CN)
- Kunming Medical University (CN)
- Shanxi Provincial Cancer Hospital (CN)
- Shangqiu First People's Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- Third Xiangya Hospital (CN)
- Shanxi Provincial People’s Hospital (CN)
- Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1016/j.tranon.2026.103113
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00